ISIku Shirasugi

Iku Shirasugi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iku Shirasugi has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort

    by Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Yuichi Maeda, So Kuroda, Takaaki Noguchi, Takayuki Fujii, Akira Onishi, Tadashi Okano, Motomu Hashimoto, et al.

    Objectives: To compare treatment effectiveness and safety among five Janus kinase inhibitors (JAKi) in patients with RA and to identify factors associated with treatment discontinuation in real-world clinical practice. Methods: This retrospective multicentre study used data from the ANSWER (Kansai Consortium for Well-being of Rheumatic Disease Patients) cohort in Japan. RA treatment courses initiating tofacitinib, baricitinib, peficitinib, upadacitinib or filgotinib between 2013 and 2025 were included. Treatment discontinuation due to ineffectiveness and adverse events was evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards models with multiple imputation. Analyses were adjusted for patient, disease and treatment characteristics, including prior treatment history. Results: A total of 1798 treatment courses from 1240 patients were analysed. Discontinuation risk due to ineffectiveness was lower with upadacitinib [hazard ratio (HR) 0.33, 95% CI 0.24–0.47] and filgotinib (HR 0.59, 95% CI 0.42–0.85) than with tofacitinib (reference), baricitinib (HR 0.82, 95% CI 0.63–1.06) and peficitinib (HR 1.23, 95% CI 0.89–1.70). Differences in discontinuation due to adverse events were observed only between upadacitinib (HR 0.57, 95% CI 0.38–0.85) and peficitinib (reference). Prior IL-6i or JAKi use increased ineffectiveness-related discontinuation for tofacitinib, baricitinib and peficitinib, but not upadacitinib (IL-6i/JAKi: HR 0.67/1.14, 95% CI 0.38–1.16/0.65–1.98) or filgotinib (HR 0.83/1.38, 95% CI 0.45–1.53/0.72–2.65). Conclusion: Treatment effectiveness and safety differed among JAKi in real-world clinical practice. Upadacitinib and filgotinib were associated with higher treatment persistence, and the adverse impact of prior IL-6i or JAKi exposure was not evident for these agents.

  • Open Access

    Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study

    by Daisuke Tomita, Yuji Nozaki, Rika Fukuda, Yumi Morimoto, Hirotaka Yamazawa, Kaori Ishimura, Chisato Ashida, Tetsu Itami, Toshihiko Shiga, Wataru Yamamoto, et al.

  • Successful salvage treatment with baricitinib for macrophage activation syndrome complicating adult-onset Still’s disease during interleukin-6 inhibition: A case report and literature review

    by Kazuma Nishisaka, Yo Ueda, Iku Shirasugi, Hirotaka Yamada, Takaichi Okano, Keisuke Nishimura, Sho Sendo, Jun Saegusa

    Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder, and macrophage activation syndrome is a life-threatening hyperinflammatory complication. Interleukin-1 and interleukin-6 inhibitors have improved outcomes in refractory AOSD, but optimal management of macrophage activation syndrome, particularly when it develops during biologic therapy, remains uncertain. We report a case of a 49-year-old woman with articular-predominant AOSD who developed fulminant macrophage activation syndrome while receiving high-dose glucocorticoids, tacrolimus, and the interleukin-6 receptor inhibitor tocilizumab. At the onset of macrophage activation syndrome, she had persistent fever, cytopenia, hyperferritinemia, and liver dysfunction, and bone marrow examination revealed haemophagocytosis. Macrophage activation syndrome persisted despite two courses of intravenous methylprednisolone pulse therapy and continuation of tocilizumab. Tocilizumab was discontinued, and treatment was switched to the oral Janus kinase 1/2 inhibitor baricitinib in combination with glucocorticoids and tacrolimus. After this change, the patient experienced rapid defervescence, marked improvement in blood counts and ferritin levels, and sustained control of articular and systemic disease activity. Glucocorticoids were successfully tapered without relapse, and the patient remained in remission for more than 2 years without serious infections. To contextualise this case, we reviewed published reports on Janus kinase inhibition in AOSD, including cases complicated by macrophage activation syndrome. Multi-cytokine blockade through Janus kinase 1/2 inhibition, targeting overlapping interleukin-6, interferon-gamma, and granulocyte–macrophage colony-stimulating factor pathways, may simultaneously suppress macrophage activation and systemic inflammation. This case highlights the potential of baricitinib as a therapeutic option for refractory AOSD-associated macrophage activation syndrome during interleukin-6 inhibition.


  • Real-world clinical outcomes of patients with disproportionate articular pain in rheumatoid arthritis: ANSWER cohort study

    by K Murata, T Fujii, K Ebina, Y Etani, M Katayama, Y Nozaki, C Ashida, T Okano, M Hashimoto, T Kotani, et al.

    In rheumatoid arthritis (RA), some patients experience joint pain that is disproportionate to the number of swollen joints, known as disproportionate articular pain (DP). This study aimed to clarify the prevalence and persistence of DP and to compare the outcomes across biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). From the ANSWER cohort in Japan, 5489 RA patients who initiated b/tsDMARDs between January 2010 and June 2024 were screened. DP was defined as having at least seven more tender joints (TJC) than swollen joints at baseline, and 432 patients met this criterion. Persistence of DP at 3 and 6 months was evaluated. Comparative analyses were conducted across mechanisms of action (MOAs): tumour necrosis factor-α inhibitors (TNFi), cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin (CTLA4-Ig), interleukin-6 inhibitors (IL-6i), and Janus kinase inhibitors (JAKi). DP was identified in 7.8% of RA patients. At 3 months, DP persisted in 40.7% (TNFi), 36.5% (CTLA4-Ig), 48.0% (IL-6i), and 54.4% (JAKi). At 6 months, corresponding rates were 43.8%, 38.7%, 49.3%, and 61.1%. Multivariate analysis showed that higher TJC and previous treatment with two or more b/tsDMARDs were associated with persistent DP, whereas higher C-reactive protein was protective. Within JAKi, baricitinib showed lower DP persistence compared with other JAKi. DP was present in approximately 8% of RA patients. Persistent DP was associated with higher TJC, greater number of previous b/tsDMARDs, and lower inflammation. No MOA was clearly superior; however, baricitinib may confer a relative benefit within the JAKi class.

  • Open Access

    Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study

    by Yuki Etani, Yasutaka Okita, Yuichi Maeda, Kohei Tsujimoto, Takaaki Noguchi, Ryu Watanabe, Motomu Hashimoto, Iku Shirasugi, Naoki Nakano, Yuji Nozaki, et al.


  • Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score–matched real-world study accounting for poor prognostic factors

    by Yuji Nozaki, Toshihiko Shiga, Jinhai Ri, Tetsu Itami, Daisuke Tomita, Hirotaka Yamazawa, Yumi Morimoto, Rika Fukuda, Takashi Tsuchimoto, Sayo Morita, et al.


  • Open Access

    Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort

    by Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Takaaki Noguchi, Koichi Murata, Takayuki Fujii, Iku Shirasugi, Mai Yamashita, Koji Nagai, Ayaka Yoshikawa, et al.

    Objectives In Japan, pharmacological treatment for rheumatoid arthritis (RA), including biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi), is provided by both orthopaedic surgeons and rheumatologists. However, differences in patient characteristics, treatment selection, and outcomes between these two clinical settings have not been fully elucidated. This study aimed to compare these factors using real-world data. Methods Using the ANSWER cohort, we identified 7268 RA treatment courses initiating bDMARDs or JAKi between August 2002 and May 2023. Patients were classified into orthopaedic surgeon–managed and rheumatologist-managed groups. Patient characteristics and treatment patterns were compared. Treatment retention due to ineffectiveness and adverse events was assessed using Cox proportional hazards models to estimate hazard ratios (HRs) adjusted for potential confounders. Results Compared with the rheumatologist-managed group, patients managed by orthopaedic surgeons had longer disease duration, higher seropositivity, greater functional impairment, although lower comorbidity prevalence such as hypertension, dyslipidemia, and diabetes mellitus. Methotrexate, tumor necrosis factor inhibitors, JAKi, and intra-articular injections were used more frequently, whereas oral glucocorticoids were used less frequently. After adjustment, treatment retention due to ineffectiveness was comparable between groups (HR 0.98, 95% CI 0.83–1.17), and changes in disease activity were similar. Discontinuation due to adverse events was significantly less frequent in the orthopaedic surgeon–managed group (HR 0.61, 95% CI 0.46–0.82). Conclusions Despite differences in patient profiles and treatment patterns, molecular-targeted therapy managed by orthopaedic surgeons achieved comparable effectiveness and was associated with a lower risk of discontinuation due to adverse events compared with rheumatology care. Key Points • Patients managed by orthopaedic surgeons had longer disease duration, higher seropositivity, and more advanced structural and functional impairment than those managed by rheumatologists. • Despite these differences, treatment effectiveness and disease activity improvement with bDMARDs or JAK inhibitors were comparable between specialties after adjustment for confounders. • Treatment discontinuation due to adverse events was less frequent in patients managed by orthopaedic surgeons. • Guideline-based management may enable consistent clinical outcomes across different specialties in real-world rheumatoid arthritis care.

  • Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study

    by Kosuke Ebina, Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Yuichi Maeda, Takaaki Noguchi, Makoto Hirao, Koichi Murata, Takayuki Fujii, Motomu Hashimoto, et al.

    Aim: This multicenter retrospective study evaluated the differential impact of concomitant methotrexate (MTX) and glucocorticoids (GCs) administration by dosage on the effectiveness and safety of biological disease‐modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi) in a real‐world cohort of patients with rheumatoid arthritis, adjusting for clinical backgrounds variables. Methods: The study included 3751 treatment courses (bDMARD‐ or JAKi‐naïve cases, 48.9%; tumor necrosis factor inhibitors: 1668; tocilizumab [TCZ]: 865; abatacept [ABT]: 825; JAKi: 393). Hazard ratios for treatment retention were calculated using multivariate Cox proportional hazards models, adjusted for potential confounders. Improvement in the clinical disease activity index (ΔCDAI) with each formulation was analyzed using mixed‐effects models for repeated measures, stratified by concomitant MTX and GCs dosages. Results: Compared to MTX(−), a lower dose of MTX (< 10 mg/week) was associated with significant improvement in ΔCDAI with golimumab (GLM), TCZ, and JAKi and reduced discontinuation due to ineffectiveness of etanercept (ETN). A higher MTX dose (≥ 10 mg/week) demonstrated a similar trend. Compared to GCs(−), a lower dose of GCs (≤ 5 mg/day; prednisolone equivalent) was associated with a diminished ΔCDAI with GLM and an increased discontinuation due to ineffectiveness of ADA and GLM. A higher dose of GCs (> 5 mg/day) was associated with increased discontinuation due to safety with ETN, CZP, and JAKi. Conclusions: The effects of concomitant MTX and GCs dosages on the effectiveness and safety of biologics and JAKi vary among agents. MTX did not mitigate safety issues, and GCs did not enhance effectiveness of any agents, regardless of dosage.


  • Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort

    by Kohei Tsujimoto, Kosuke Ebina, Satomi Okamura, Yasutaka Okita, Yuki Etani, Wataru Yamamoto, Akira Onishi, Hideo Onizawa, Iku Shirasugi, Naoki Nakano, et al.

    Objectives: This multicentre, retrospective study aimed to evaluate differences in drug continuation rates and efficacy between first- and second-line use of biological DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi) after failure of the initial therapy in real-world RA settings. Methods: Data from an observational multicentre registry of patients with RA in Japan were analysed, encompassing 5900 treatment courses (4046 bDMARD/JAKi-naïve cases and 1854 second-line cases). Gray’s tests were used to compare the cumulative incidence function (CIF) for drug discontinuation, considering discontinuation due to remission as a competing risk. Competing risk analysis using Fine–Gray model was conducted to analyse the hazard ratios after adjusting for potential confounders. Changes in the Clinical Disease Activity Index (ΔCDAI) and disease activity score (ΔDAS28-CRP) were assessed at each time point compared with baseline using a linear mixed model with covariate adjustments. Results: Among the TNF inhibitors, IL-6 inhibitors, Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and JAKi, only JAKi showed no significant difference in CIF of first- and second-line treatments. Competing risk analysis showed that consistent with the CIF analysis, second-line treatment influenced the drug continuation rates for all drugs except for JAKi. In analysing CDAI and DAS28-CRP trends using a linear mixed model, JAKi demonstrated similar efficacy as first- and second-line therapy, unlike other drugs. Conclusions: JAKi maintained continuation rates and efficacy in second-line treatment compared with first-line treatment, which is potentially advantageous over bDMARDs for patients with RA who require a change in initial therapy.